Literature DB >> 19643163

Selective labeling of IRAP by the tritiated AT(4) receptor ligand [3H]Angiotensin IV and its stable analog [3H]AL-11.

Heidi Demaegdt1, Aneta Lukaszuk, Evi De Buyser, Jean-Paul De Backer, Erzsébet Szemenyei, Géza Tóth, Sridhara Chakravarthy, Mitradas Panicker, Yvette Michotte, Dirk Tourwé, Georges Vauquelin.   

Abstract

'AT(4) receptors' through which Angiotensin IV (Ang IV) improves memory acquisition, were recently identified as insulin regulated aminopeptidase (IRAP). Radioligand binding studies have hitherto been performed with iodinated Ang IV in the presence of divalent cation chelators EDTA and 1,10-phenanthrolin. Hence, they referred to the apo-form of IRAP. Presently, binding of [(3)H]Ang IV and [(3)H]AL-11, a stable Ang IV analog, was compared on Chinese hamster ovary (CHO-K1) and mouse hippocampal (P40H1) cell membranes. With chelators, their high affinity sites showed the same pharmacological profile as for [(125)I]Ang IV binding. Without chelators, only high affinity binding was perceived for [(3)H]AL-11. The same pharmacological profile was recorded in both membrane preparations; it was different from the one in the presence of chelators and corresponded to catalytically active IRAP (despite the concurrent presence of aminopeptidase N (APN) in P40H1 cell membranes). This confirms that the active and apo-forms of IRAP have a distinct pharmacological profile.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19643163     DOI: 10.1016/j.mce.2009.07.020

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  3 in total

Review 1.  Analysis of mouse brain peptides using mass spectrometry-based peptidomics: implications for novel functions ranging from non-classical neuropeptides to microproteins.

Authors:  Lloyd D Fricker
Journal:  Mol Biosyst       Date:  2010-04-28

2.  Discovery of inhibitors of insulin-regulated aminopeptidase as cognitive enhancers.

Authors:  Hanna Andersson; Mathias Hallberg
Journal:  Int J Hypertens       Date:  2012-12-04       Impact factor: 2.420

Review 3.  From Angiotensin IV to Small Peptidemimetics Inhibiting Insulin-Regulated Aminopeptidase.

Authors:  Mathias Hallberg; Mats Larhed
Journal:  Front Pharmacol       Date:  2020-10-15       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.